Atomi Financial Group Inc. Has $240,000 Holdings in Becton, Dickinson and Company (NYSE:BDX)

Atomi Financial Group Inc. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 25.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,056 shares of the medical instruments supplier’s stock after buying an additional 213 shares during the period. Atomi Financial Group Inc.’s holdings in Becton, Dickinson and Company were worth $240,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $26,000. Ashton Thomas Securities LLC acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $33,000. Tompkins Financial Corp increased its holdings in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares during the period. Sound Income Strategies LLC increased its holdings in shares of Becton, Dickinson and Company by 35.8% in the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Finally, Kennebec Savings Bank acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $46,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Roland Goette sold 4,483 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the sale, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. This represents a 15.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP David Shan sold 500 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the sale, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 9,844 shares of company stock valued at $2,210,716 over the last 90 days. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Up 1.3 %

Shares of Becton, Dickinson and Company stock opened at $243.69 on Monday. The stock has a market capitalization of $70.67 billion, a P/E ratio of 41.02, a PEG ratio of 1.72 and a beta of 0.39. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. The stock has a 50 day moving average price of $228.08 and a two-hundred day moving average price of $233.08. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $248.42.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The company’s revenue was up 6.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.42 earnings per share. Equities analysts expect that Becton, Dickinson and Company will post 14.42 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were given a dividend of $1.04 per share. The ex-dividend date was Monday, December 9th. This represents a $4.16 dividend on an annualized basis and a yield of 1.71%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their target price for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Finally, Evercore ISI boosted their price target on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $283.50.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.